In a study published in Neurology, a group from Alnylam Pharmaceuticals used large-scale protein screening assays to simultaneously analyse many proteins in vast numbers of patient serum samples. This approach allowed them to discover a novel biomarker of hereditary transthyretin-mediated (ATTRv) amyloidosis disease onset and progression. ATTRv amyloidosis, caused by mutation… Read More
Kim Ekroos PhD, Founder & CEO Lipidomics Consulting and Kelly Moser PhD, Lab Operations Manager and Applications Scientist, MOBILion Systems examine advancements in research of biomarkers for early diagnostics and effective treatments for neurodegenerative disorders with High-Resolution Ion Mobility Mass Spectrometry Although the first descriptions and classifications of lipids appeared… Read More
Immodulon, the immuno-oncology company, will present at the 11th World Clinical Biomarkers & Companion Diagnostic Europe Event taking place virtually 24-25 March 2021. The presentation, titled ‘Clinical Biomarker Strategy with a Complex Immunomodulator: The Must-Haves & the Nice-To-Haves On a Limited Budget’, will be presented at 12:45 CET, March 25, 2021,… Read More
Metabolon and Cleveland Clinic have entered into multi-year collaborative agreement to accelerate research, drug development and precision medicine. Metabolon will leverage its proprietary platform to analyse a range of biologic samples to help discover metabolomic biomarkers that will deepen understanding of Cleveland Clinic’s novel discoveries, improve speed of decision-making and… Read More
Evotec has entered into an integrated multi-target drug discovery agreement with biotech venture creation firm Related Sciences to generate multiple drug development candidates, biomarkers, and IND filings over a multi-year period. Evotec and Related Sciences will jointly discover and develop a range of therapeutic approaches for clearly defined patient populations… Read More
Deep Pharma Intelligence announces the release of a new, open-access 130-page analytical report and interactive analytics Dashboard: AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2020. This delivers advanced market intelligence, interactive mindmaps, benchmarking for companies, investors and technologies, competitive and SWOT analysis through the interactive IT-Platform and… Read More
Brigham and Women’s Hospital researchers analysed patients’ levels of inflammation, known to be associated with severity of illness, by looking at C-reactive protein (CRP) trends in 100 COVID-19 patients admitted to the hospital. They found that a rapid rise in CRP levels during the first 48-to-72 hours of hospitalisation was… Read More
A new study from Lawson Health Research Institute, Western University and University of Alberta suggests that COVID-19 affects the human body’s blood concentration levels of specific metabolites – small molecules broken down in the human body through the process of metabolism. Three specific metabolites identified in this study could act… Read More
BioIVT will be hosting a virtual Emerging Technologies in Diagnostics Symposium on Thursday, October 29 (10am-1pm ET). “The diagnostic assay landscape is changing rapidly as the demand for faster, less expensive, more precise diagnostics continues to grow,” said Cathie Miller, Director of Product Marketing, Personalised Medicine at BioIVT. “We wanted… Read More
Luis Valente, CEO & Co-Founder of iLoF, has been recognized by Forbes as one of the top 30 under 30 for science and healthcare. He told Lu Rahman what’s behind his start-up that recently secured $1 million in investment from Microsoft’s Venture Fund, M12 and Mayfield Fund and won the… Read More
By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the public policy level to… Read More
By Dr Karin Bottcher High content screening (HCS) has played a significant role in infectious disease research and drug discovery to date and can be a strong tool in the age of COVID-19 and beyond. With a focus on viral diseases, this article will describe how HCS has been used… Read More
Honing in on perfect targeting By Dr Samantha Zaroff Volume 21 Issue 3 - Summer 2020 The pros and cons of different delivery modalities for personalised cancer vaccines. Introducing neoantigens directly into a patient in order to elicit an anti-tumour killing immune response is known as personalised cancer vaccine therapy. Read More
The CELL CULTURE innovations increasing drug discovery success By Helen Stewart-Miller and Abby George Volume 21 Issue 3 - Summer 2020 'Fail early, fail fast' has been a mantra in the pharmaceutical industry for several years and directly impacts the overall strategy of many drug discovery and development programmes. Yet,… Read More
The Personalized Medicine Coalition The Personalized Medicine Coalition (PMC), representing a broad spectrum of academic, industrial, patient, provider, and payer communities, seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. As part of its mission, the PMC publishes The Case for… Read More
Collaborative Research Leads To New Understanding Of Biomarkers By Dr Max Ryadnov and Professor Jason Crain A new collaborative research paper sheds light on the way antibodies distinguish between different but closely related ‘biomarkers’ – in this case protein fragments which reveal information about the condition of the human body. Read More
